vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and Serve Robotics Inc. (SERV). Click either name above to swap in a different company.
Serve Robotics Inc. is the larger business by last-quarter revenue ($881.5K vs $838.0K, roughly 1.1× Prime Medicine, Inc.). Serve Robotics Inc. runs the higher net margin — -3888.1% vs -5498.7%, a 1610.6% gap on every dollar of revenue. On growth, Serve Robotics Inc. posted the faster year-over-year revenue change (400.1% vs -61.6%). Prime Medicine, Inc. produced more free cash flow last quarter ($-37.5M vs $-46.1M).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Ecovacs Robotics is a Chinese technology company. It is best known for developing in-home robotic appliances. The company was founded in 1998 by Qian Dongqi and is headquartered in Suzhou, China. According to Global Asia, Ecovacs Robotics had more than 60% of the Chinese market for robots by 2013. In 2023, Nikkei Asia had reported that the market capitalisation of Ecovacs Robotics has grown to near $6.38 billion, which is "roughly 5 times" that of the market capitalisation of rivalling US bas...
PRME vs SERV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $881.5K |
| Net Profit | $-46.1M | $-34.3M |
| Gross Margin | — | -757.3% |
| Operating Margin | -5800.5% | -4572.1% |
| Net Margin | -5498.7% | -3888.1% |
| Revenue YoY | -61.6% | 400.1% |
| Net Profit YoY | -9.0% | -161.3% |
| EPS (diluted) | $-0.22 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | $881.5K | ||
| Q3 25 | $1.2M | $687.0K | ||
| Q2 25 | $1.1M | $642.0K | ||
| Q1 25 | $1.5M | $440.5K | ||
| Q4 24 | $2.2M | $176.3K | ||
| Q3 24 | — | $222.0K | ||
| Q2 24 | $0 | $468.0K | ||
| Q1 24 | $591.0K | $946.7K |
| Q4 25 | $-46.1M | $-34.3M | ||
| Q3 25 | $-50.6M | $-33.0M | ||
| Q2 25 | $-52.6M | $-20.9M | ||
| Q1 25 | $-51.9M | $-13.2M | ||
| Q4 24 | $-42.3M | $-13.1M | ||
| Q3 24 | — | $-8.0M | ||
| Q2 24 | $-55.3M | $-9.0M | ||
| Q1 24 | $-45.8M | $-9.0M |
| Q4 25 | — | -757.3% | ||
| Q3 25 | — | -637.4% | ||
| Q2 25 | — | -445.3% | ||
| Q1 25 | — | -333.4% | ||
| Q4 24 | — | -371.7% | ||
| Q3 24 | — | -70.3% | ||
| Q2 24 | — | 30.3% | ||
| Q1 24 | — | 62.8% |
| Q4 25 | -5800.5% | -4572.1% | ||
| Q3 25 | -4406.0% | -5067.8% | ||
| Q2 25 | -4787.2% | -3527.1% | ||
| Q1 25 | -3603.3% | -3406.6% | ||
| Q4 24 | -2025.7% | -7701.3% | ||
| Q3 24 | — | -3804.1% | ||
| Q2 24 | — | -1828.2% | ||
| Q1 24 | -8179.5% | -814.6% |
| Q4 25 | -5498.7% | -3888.1% | ||
| Q3 25 | -4129.1% | -4806.4% | ||
| Q2 25 | -4716.7% | -3247.7% | ||
| Q1 25 | -3568.8% | -3000.5% | ||
| Q4 24 | -1936.6% | -7441.8% | ||
| Q3 24 | — | -3601.8% | ||
| Q2 24 | — | -1931.2% | ||
| Q1 24 | -7743.0% | -954.7% |
| Q4 25 | $-0.22 | $-0.50 | ||
| Q3 25 | $-0.32 | $-0.54 | ||
| Q2 25 | $-0.41 | $-0.36 | ||
| Q1 25 | $-0.40 | $-0.23 | ||
| Q4 24 | $-0.31 | $-0.23 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | $-0.46 | $-0.27 | ||
| Q1 24 | $-0.44 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $106.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $350.7M |
| Total Assets | $342.7M | $367.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $106.2M | ||
| Q3 25 | $71.4M | $116.8M | ||
| Q2 25 | $53.8M | $116.7M | ||
| Q1 25 | $91.9M | $197.8M | ||
| Q4 24 | $182.5M | $123.3M | ||
| Q3 24 | — | $50.9M | ||
| Q2 24 | $55.6M | $28.8M | ||
| Q1 24 | $94.2M | — |
| Q4 25 | $120.9M | $350.7M | ||
| Q3 25 | $161.8M | $283.9M | ||
| Q2 25 | $60.9M | $207.2M | ||
| Q1 25 | $106.9M | $210.2M | ||
| Q4 24 | $153.1M | $131.7M | ||
| Q3 24 | — | $56.2M | ||
| Q2 24 | $196.6M | $28.5M | ||
| Q1 24 | $243.8M | $-8.8M |
| Q4 25 | $342.7M | $367.8M | ||
| Q3 25 | $385.0M | $299.1M | ||
| Q2 25 | $279.0M | $214.3M | ||
| Q1 25 | $328.2M | $216.6M | ||
| Q4 24 | $297.5M | $139.6M | ||
| Q3 24 | — | $61.5M | ||
| Q2 24 | $259.7M | $32.8M | ||
| Q1 24 | $311.4M | $4.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-29.6M |
| Free Cash FlowOCF − Capex | $-37.5M | $-46.1M |
| FCF MarginFCF / Revenue | -4480.4% | -5234.4% |
| Capex IntensityCapex / Revenue | 34.6% | 1872.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | $-117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | $-29.6M | ||
| Q3 25 | $-35.0M | $-25.2M | ||
| Q2 25 | $-41.4M | $-16.0M | ||
| Q1 25 | $-48.9M | $-9.5M | ||
| Q4 24 | $16.2M | $-6.3M | ||
| Q3 24 | — | $-5.5M | ||
| Q2 24 | $-45.5M | $-5.7M | ||
| Q1 24 | $-67.7M | $-4.1M |
| Q4 25 | $-37.5M | $-46.1M | ||
| Q3 25 | $-35.3M | $-36.5M | ||
| Q2 25 | $-43.0M | $-22.0M | ||
| Q1 25 | $-51.3M | $-12.9M | ||
| Q4 24 | $14.5M | $-11.1M | ||
| Q3 24 | — | $-10.1M | ||
| Q2 24 | $-47.4M | $-6.5M | ||
| Q1 24 | $-70.0M | $-4.1M |
| Q4 25 | -4480.4% | -5234.4% | ||
| Q3 25 | -2880.5% | -5314.1% | ||
| Q2 25 | -3855.1% | -3426.8% | ||
| Q1 25 | -3526.8% | -2934.1% | ||
| Q4 24 | 662.1% | -6307.8% | ||
| Q3 24 | — | -4529.7% | ||
| Q2 24 | — | -1396.6% | ||
| Q1 24 | -11849.6% | -431.1% |
| Q4 25 | 34.6% | 1872.1% | ||
| Q3 25 | 20.2% | 1649.6% | ||
| Q2 25 | 141.0% | 940.4% | ||
| Q1 25 | 166.6% | 785.7% | ||
| Q4 24 | 82.0% | 2755.1% | ||
| Q3 24 | — | 2070.7% | ||
| Q2 24 | — | 169.8% | ||
| Q1 24 | 393.2% | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
